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Abstract Canine distemper virus (CDV) is a morbillivi-
rus related to measles virus that infects dogs and other
carnivores. CDV has a significant global impact on animal
health; however, there is no current antiviral treatment for
CDV infection. In recent years, it has been demonstrated
that sulfated polysaccharides exhibit antiviral properties
both in vivo and in vitro, despite their low cytotoxicity to
host cells. Fucoidan is a sulfated polysaccharide found in
the cell wall matrix of brown algae. In this study, we
evaluated in vitro anti-CDV activity of fucoidan, which
was derived from Cladosiphon okamuranus. Fucoidan
actively inhibited CDV replication in Vero cells at a 50 %
inhibitory concentration (IC50) of 0.1 lg/ml. The derived
selectivity index (SI50) was [20,000. This polysaccharide
likely inhibits viral infection by interference in the early
steps and by inhibiting CDV-mediated cell fusion. Fucoi-
dan may be useful in development of pharmacological
strategies to treat and control CDV infection.
Keywords Fucoidan  CDV  Antiviral  Cladosiphon
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Introduction
Canine distemper virus (CDV) is a negative-stranded RNA
morbillivirus related to measles virus. CDV infection
causes severe morbidity and mortality in dogs and other
carnivores and significantly affects animal health world-
wide [22]. Despite an increasing demand from veterinari-
ans and pet owners, an antiviral treatment for CDV
infection is not available; but research is in progress.
Ribavirin inhibits CDV replication in vitro in a dose- and
time-dependent manner [7]. However, ribavirin exhibited
low selectivity indexes, so it is unsuitable for clinical
treatment of CDV-infected animals.
Marine algae produce metabolites that have been rec-
ognized as promising biologically active compounds for
use as antiviral drugs. Fucoidans are complex sulfated fu-
cosylated polysaccharides produced by brown seaweeds
and have a wide spectrum of pharmacological properties
(e.g., anti-inflammatory, anti-angiogenic, anti-coagulant,
and antiviral) [2, 5, 14, 19]. Because fucoidans are present
in large quantities in dietary brown seaweed products
consumed in Asian countries, these compounds may
already have an important role in disease prevention [6].
Cladosiphon okamuranus is an edible brown alga that is
commercially cultured around Okinawa Island, Japan. Fu-
coidan is prepared from this alga on an industrial scale and
is used as an additive for health foods, drinks, and cos-
metics. Fucoidan extracted from C. okamuranus possesses
a-1-3-linked L-fucosyl residues that are substituted with D-
glucuronic acid at C-2 and with sulfate groups at C-4 of the
L-fucosyl residues. The average branched chain structure
consists of one sulfate group for every two molecules of
fucose and one glucuronic residue for every six molecules
of fucose [16]. The polysaccharide also contains xylose as
a minor monosaccharide constituent. Using a room tem-
perature extraction, Tako et al. reported an acetylfucoidan
yield of 2.3 % (w/w) based on the wet alga weight. The
total contents of carbohydrates, D-glucuronic acid, sulfuric
acid, ash, and moisture were 69, 13.5, 13.6, 23 and 3.2 %,
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respectively, and the molar ratio of L-fucose:D-xylose:D-
glucuronic acid:acetic acid:sulfuric acid was estimated to
be 4.0:0.03:1.0:2.0:2.0 [24]. In contrast with other sulfated
polysaccharides, Cladosiphon fucoidan does not promote
an inflammatory response in vitro [21] and lacks anti-
angiogenic and anti-coagulant activities [4]. Cladosiphon
okamuranus fucoidan is not toxic to hepatocytes and has no
adverse effects on the serum electrolytes of Wistar rats
[10]. However, similar doses potently inhibit dengue virus
type 2 (DEN2) replication [12] and significantly inhibit the
proliferation of HTLV-1-infected T-cells [11]. In the
present study, we examined the in vitro anti-CDV activity
of fucoidan derived from C. okamuranus, and compared
this activity to ribavirin.
Materials and methods
Fucoidan and ribavirin
Fucoidan was purchased as a dried powder from Kadoya &
Co., Kobe, Japan (lot A03012) and extracted from cultured
kelp C. okamuranus harvested off the coast of Okinawa
Island, Japan [24]. The polysaccharide preparation was cer-
tified to contain 90.4 % fucoidan (anthrone-sulfuric acid
method) and to have a mean molecular weight of 92.1 kDa
(HPLC method). The fucose and sulfate contents of fucoidan
were 38.6 and 15.9 %, respectively, with ash comprising
19.6 % of the content and other sugars comprising 23 %
(glucuronic acid and traces of xylose). Dried samples of fu-
coidan were suspended in Dulbecco’s modified Eagle’s
medium (DMEM) at a concentration of 2.5 mg/ml and filtered
through a 0.22 mm membrane filter. Ribavirin (Vilonape-
diatrica, Valeant, Me´xico) was used as an antiviral control.
Cells culture and virus
African green monkey kidney cells (Vero cells) were
grown as monolayers in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal calf
serum (FCS) and 1 % penicillin and streptomycin. Vero
cells were cultured at 37 C in a 5 % CO2 incubator.
Canine distemper virus (CDV; Onderstepoort strain)
adapted to Vero cells was titrated by plaque forming units
(PFU). Virus aliquots were stored at -70 C until use.
Cytotoxicity assay
The conventional MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) method [15], with some
modifications, was used to evaluate cytotoxicity. Vero cells
were seeded in 96-well plates at an initial density of
5 9 103 cells per well. After the cells were incubated for
20 h at 37 C, various concentrations of the antiviral
compounds fucoidan (1, 10, 100, 500 and 1,000 lg/ml) or
ribavirin (0.1, 1, 10 and 100 lg/ml) were added to the
growth medium, with six wells for each concentration. The
cultures were then incubated for an additional 72 h. MTT
solution (20 ll well) at a concentration of 5 mg/ml was
added to each well and cells were incubated at 5 % CO2
and 37 C for 4 h. The medium and excess MTT were
removed from each well, and 100 ll dimethyl sulfoxide
was added to dissolve the formazan crystals. The optical
density was measured at 570 and 690 nm using a Micro-
plate Autoreader EL311 (BIOTEK Instruments Inc., USA).
Each experiment was repeated three times. Cytotoxicity
was expressed as 50 % cytotoxic concentration (CC50),
which was the concentration of the test substances that
inhibited up to 50 % of the growth of Vero cells.
Virus plaque reduction assays
Fucoidan was tested for anti-viral activity against CDV
with a plaque reduction assay using Vero cell monolayers
in six-well culture plates. The assay was performed by
adding the compound during all assay (72 h). For a typical
assay, 100 plaque forming units (PFUs) were incubated
with increasing concentrations of fucoidan (0.1, 1 and
10 lg/ml) for 1 h at room temperature. Virus was allowed
to adsorb to the cells for 1 h at 37 C. The residual inoc-
ulum was then discarded and infected cells were overlaid
with medium containing 0.6 % agar (MP Biomedicals, Inc)
and the indicated concentrations of the sulfated polysac-
charide. Each concentration was performed in triplicate.
After incubation of 72 h at 37 C to allow for plaque for-
mation, the cells were fixed with methanol and stained with
1 % crystal violet. Plaques in the Vero cell monolayer were
counted. Using dose–response curves, plaque reduction by
the test compounds was determined by, and expressed as,
the test compound concentration that inhibited plaque
formation by 50 % (IC50).
Time of addition assays
In order to analyze the inhibitory mechanism of fucoidan
against CDV, infected cells were treated with increasing
concentrations (0.001–10 lg/ml) for various periods of
time prior to, during, and after infection with CDV. Fu-
coidan antiviral activity was compared with ribavirin in
post-adsorption assays.
Drug treatment before virus infection or concurrent
with infection
Vero cells were treated with increasing concentrations of
fucoidan (0.001–10 lg/ml) for 1 h at 37 C prior to CDV
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infection. After incubation, the cells were washed three
times with phosphate buffered saline to ensure the com-
plete removal of fucoidan from the media, then infected
with 100 PFU per well of CDV and incubated at 37 C for
1 h. The infected cell monolayer was then washed three
times with phosphate buffered saline, overlaid with med-
ium containing 0.6 % agar (MP Biomedicals, Inc.), and
incubated for 72 h at 37 C. A second assay was performed
with cells infected at the same time as fucoidan treatment.
The virus suspension was mixed with the indicated con-
centration of fucoidan before adding it to the cell mono-
layer. Vero cells were treated with the mix for 1 h at 37 C,
then removed from cell media by extensively washed and
the monolayer was cultured for plaque assay as previously
described.
Drug treatment after virus adsorption
Cells were infected with CDV for 1 h at 37 C. After
incubation, the infected cell monolayer was then washed
three times with phosphate buffered saline and increasing
concentrations of fucoidan or ribavirin were then added
and cells were incubated at 37 C for 1 h. The infected cell
monolayer was then washed three times with phosphate
buffered saline, overlaid with medium containing 0.6 %
agar, and incubated for 72 h at 37 C.
Viral syncytium inhibition assay
Virus-induced cell fusion assays were used to examine the
ability of fucoidan to inhibit CDV induced syncytia for-
mation. Vero cells were cultured in 6-well plates in
DMEM, supplemented with 10 % FCS. Cell monolayers
were infected with CDV at 100 PFU per well. After
adsorption for 1 h, the inoculum was replaced by DMEM
with 2 % FCS and dilutions of fucoidan in medium without
FCS were added. At 24 h post infection, the cells were
fixed and stained with 1 % (w/v) crystal violet in 100 %
methanol. The number of nuclei was counted for 20 syn-
cytia per well, and inhibition of syncytium size was
determined.
Data analysis
Data were analyzed using SPSS 10 software (IBM, Ar-
monk, New York, USA). Probit regression analysis was
used to determine CC50, which was the concentration of the
test substance that reduced the optical density by 50 %,
compared with the controls. The IC50 was the concentra-
tion that reduced PFU number by 50 %. The selectivity
index (SI) was the ratio CC50/IC50. The CC50 and IC50
values were estimated from the mean and standard devia-
tions or standard errors (time of addition assays) of the
mean values from three independent experiments.
Results
Cytotoxicity assay
The cytotoxicity of fucoidan and ribavirin to Vero cells
was evaluated. As shown in Fig. 1, although the no effect
on cytotoxicity was detected for fucoidan at concentrations
up to 10 lg/ml (CC50 = 2,089 lg/ml ± 6 SD). However,
10 lg/ml ribavirin was toxic to Vero cells (CC50 =
88.9 lg/ml ± 6 SD). For the remainder of the studies, the
antiviral activity of these compounds was assessed at
concentrations below 10 lg/ml to rule out non-specific
inhibition due to cell cytotoxicity.
Fucoidan inhibits CDV replication
To assess fucoidan inhibition of CDV replication, Vero cell
monolayers were treated with increasing concentrations of
fucoidan that was added at the same time, each well
received 100 PFUs of CDV. The same concentration of
A B
Fig. 1 Evaluation of fucoidan (A) and ribavirin (B) cytotoxicity to Vero cells using the MTT assay. Control: cells without treatment. Bars
represent means, with vertical lines indicating standard deviations, n = 9, *p B 0.05
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fucoidan was maintained in the plaque assay overlay
medium throughout the infection. Antiviral activity was
evaluated by observing a reduction in the number of CDV
plaques. The results demonstrated significant and repro-
ducible antiviral activity of fucoidan against CDV (Fig. 2).
Fucoidan treatment reduced not only the number but also
the size of plaques (data not shown). Fucoidan inhibition
resulted in an IC50 \ 0.1 lg/ml. The resulting selectivity
index (SI; [20,000 CC50/IC50) indicated that fucoidan
potently inhibited CDV at a very low drug concentration,
and was not cytotoxic.
Effect of fucoidan on virus adsorption and entry
Vero cells were pretreated with various concentrations of
fucoidan (0.001–10 lg/ml), which was removed before
incubation with CDV by extensively washed. The results
indicated that they were protected from CDV infection in a
manner that was not strictly dose-dependent (Fig. 3a).
Additional assays were performed with fucoidan added
directly to virus suspensions. Under these conditions, the
apparent efficacy of fucoidan was slightly increased.
After virus adsorption, the unadsorbed virus was
removed and Vero cells were treated with various con-
centrations of fucoidan (0.001–10 lg/ml) or ribavirin
(0.01–10 lg/ml) as described in methodology, then washed
to ensure the complete removal of test compounds. Virus
yield was determined by plaque assay. Fucoidan displayed
anti-CDV activity when the cells were treated after virus
adsorption (Fig. 3b). However, this activity was slightly
lower than the inhibition that occurred when cells were
treated at the time of infection (Fig. 3a). Fucoidan-treated
Vero cells were much better protected from CDV infection
than ribavirin-treated cells (Fig. 3b). These experimental
results suggest that fucoidan has antiviral activity via the
inhibition of virus binding and/or penetration.
Antiviral efficacy versus cytotoxicity
Assessment of cytotoxicity is clearly an important part of
the evaluation of any potential antiviral agent. As shown in
Fig. 4, fucoidan effectively inhibits the replication of CDV
even at drug concentrations that showed no cytotoxicity. In
contrast, ribavirin was cytotoxic at drug concentrations that
inhibit CDV replication (SI \ 8.9, a [ 2000-fold differ-
ence; Fig. 4).
Fucoidan reduces cell-to-cell spread of CDV
F and H proteins of CDV are necessary for fusion of
adjacent cell membranes. The expression of CDV F protein
Fig. 2 Evaluation of antiviral activity of fucoidan against canine
distemper virus in Vero cells by plaque reduction. Infected cells were
cultured in the absence of drug, or with the indicated concentration of
fucoidan. Bars represent mean values and vertical lines represent the
standard deviations from the mean (n = 9, *p \ 0.05)
A B
Fig. 3 Effect of fucoidan on adsorption and entry of canine
distemper virus (CDV). The fucoidan was added to and incubated
for 1 h with cells either ‘‘before infection (1 h b.i.)’’ or ‘‘during
infection (0 h)’’ of cell infection with CDV (100 PFU) (A). The
fucoidan or ribavirin was added and incubated for 1 h with cells after
1 h period of cell infection with CDV (100 PFU) ‘‘post-infection (1 h
p.i.)’’ (B), following 72 h incubation. Control cells were infected with
CDV (100 PFU), but not treated with fucoidan. Bars represent mean
values and vertical lines represent the standard error from the mean
(n = 9, *p \ 0.05)
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on the cell surface results in cell–cell fusion (syncytia) and
subsequent cell-to-cell spread of progeny viruses [23].
Vero cells infected with CDV were incubated in increasing
concentrations (0.01–10 lg/ml) of fucoidan. Syncytia size
was markedly reduced by fucoidan treatment in a dose-
dependent manner (Fig. 5).
Discussion
The aim of the present study was to test and evaluate the
antiviral activity of fucoidan against CDV. Fucoidan is a
polysaccharide isolated from the brown seaweed Cladosi-
phon okamuranus, since other similar polysaccharides have
been shown to have a wide array of pharmacological
activities. This study also sought to determine the mecha-
nism(s) by which fucoidan blocked CDV infection.
Understanding the mechanism of antiviral activity of this
algal polysaccharide is important for its future develop-
ment as antiviral drugs for clinical or veterinary use.
The major undesirable side effect of sulfated polysac-
charides is their well-known anticoagulant activity. This
adverse effect can be avoided by selecting sulfated poly-
mers, such as fucoidan from C. okamuranus, which exhibit
virtually no anticoagulant activity [4]. Cumashi et al.
suggested that the high presence of glucuronic acid bran-
ches is the most likely feature responsible for the lack of
anticoagulant activity by C. okamuranus fucoidan, as the
less active compounds are characterized by a low degree of
sulfation and a high presence of 2-O-a-D-glucuronyl sub-
stituents along the linear polysaccharide backbone (char-
acteristics fucoidan from C. okamuranus) [4]. By contrast,
it has been proposed that the antiviral activity of fucoidan
is related to the concentration of fucose and uronic acids.
Hidari et al. found that the antiviral properties of fucoidan
from C. okamuranus against dengue virus type 2 vanished
when the glucuronic acid was carboxyl-reduced [12]. In the
present study, we evaluated the antiviral activity of fucoi-
dan from C. okamuranus extracted by the method of Tako
et al. with a significant degree of uronic acids, and inves-
tigated its possible mechanism of action in Vero cells [24].
Sulfated polysaccharides act primarily through inhibi-
tion of the entry of enveloped viruses into host cells [5, 9,
14]. Marine polysaccharides from different sources can
A B
Fig. 4 Fucoidan and ribavirin antiviral efficacy. Percent inhibition of
plaque forming units versus percent cytotoxicity. Test results based
on treatment with fucoidan, concurrent with infection (A) and test
results based on ribavirin treatment after adsorption (B). Bars
represent mean values and vertical lines represent the standard error
from the mean (n = 9, *p \ 0.05)
BA
Fig. 5 Effect of fucoidan on syncytium formation. (A) Circles
represent mean values and vertical lines represent standard deviation
from the mean. The mean ± standard deviation (%) for 20 syncytia
per well was determined in three different experiments (*p \ 0.05).
(B) The effect of fucoidan on syncytium size (i.e., the number of
nuclei per syncytium)
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block virus infection by interfering with the virus adsorp-
tion process. The antiviral action of fucoidan seems to stem
from inhibiting the binding of the virus particles to the host
cell and interferes with the adsorption process [1]. Certain
sulfated marine polysaccharides, can interfere with virus
internalization and the subsequent uncoating by blocking
the allosteric process of virus particles [26]. Our results
support the ability of fucoidan to block the early stages of
CDV infection by blocking viral adsorption and maybe one
or more post binding penetration steps.
Fucoidan inhibited the first steps of the viral infection
cycle and strongly suppressed the formation of CDV-
induced syncytia in infected cells perhaps by direct action
on the proteins responsible for CDV fusion (F or H) or by
inhibiting its expression. We previously found that fucoi-
dan of C. okamuranus both blocking of post-binding entry
steps of NDV to cells and strongly suppresses syncytia
formation when fucoidan was added before cleavage of the
fusion protein, feasibly indicating a specific interaction
between fucoidan and the F0 protein [8]. These apparent
multifaceted mechanisms of fucoidan action are similar to
the mechanisms of action of other sulfated polysaccharides
[3, 18, 20, 25]. Our results agree with the results of
Hoshino et al. and Nyberg et al., who demonstrated that the
mechanisms of antiviral activity of low molecular weight
sulfated polysaccharides include inhibition of the entry of
enveloped virions into host cells and inhibition of cell-to-
cell spread of the virus [13, 17]. Cytolytic viruses, such as
CDV, spread through a cell culture by producing infectious
particles and by lateral cell-to-cell fusion. Thus, virus
production observed in our studies with fucoidan might
reflect predominantly on secondary spread rather than rapid
lateral transmission, resulting in a greatly reduced syncytia
number and plaque size.
Elia et al. reported that ribavirin was active against CDV
in vitro [7]. In this study, ribavirin showed lower antiviral
activity than fucoidan, (ribavirin SI \ 9, fucoidan
SI [ 20,000). Assessment of cytotoxicity is clearly an
important part of the evaluation of a potential antiviral
agent since a useful compound should not show acute or
long-term toxicity against the host. In the study by Gideon
and Rengasamy, rats treated with C. okamuranus exhibited
no necropsy or other pathological changes in organs or
changes in histopathological morphology, consistent with
the lower toxicity possessed by sulfated polysaccharides,
specifically fucoidan from C. okamuranus [10].
This is the first report of a sulfated polysaccharide with
antiviral activity against CDV. The high selectivity of
antiviral action reported for fucoidan [20,000 is clinically
promising.
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